Xeris Biopharma Holdings, Inc. Stock Analysis & AI Score
Xeris Biopharma Holdings, Inc. (XERS) has an ST Score of 58.2 (B-), driven by its Momentum (A) and held back by its Financial Strength (C-). Analysts rate it Buy with a $14.00 price target (+56.4% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Xeris Biopharma Holdings, Inc. (XERS) has an ST Score of 58.2 (B-), driven by its Momentum (A) and held back by its Financial Strength (C-). Analysts rate it Buy with a $14.00 price target (+56.4% upside).
- Strongest
- MomentumA
- Weakest
- Financial StrengthC-
All factor grades
- MomentumA
- ProfitabilityB
- GrowthB
- ForecastB
- ValuationC
- Financial StrengthC-
- Piotroski5/9
Contact
XERS stock: frequently asked questions
What is XERS's ST Score?
Xeris Biopharma Holdings, Inc. (XERS) has an ST Score of 58.2 (B-), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is XERS a buy, hold, or sell?
Analysts rate XERS a Buy, with a price target of $14.00 (+56.4% vs the current price). Our ST Score grades it B- (58.2/100). The ST Score is a data-driven signal, not a recommendation.
What are XERS's factor grades?
Valuation C, Profitability B, Financial Strength C-, Momentum A, Growth B, Forecast B.
What is XERS's valuation grade?
Xeris Biopharma Holdings, Inc. (XERS) earns a valuation grade of C, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is XERS's growth grade?
Xeris Biopharma Holdings, Inc. (XERS) earns a growth grade of B, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is XERS's profitability grade?
Xeris Biopharma Holdings, Inc. (XERS) earns a profitability grade of B, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is XERS's financial strength grade?
Xeris Biopharma Holdings, Inc. (XERS) earns a financial strength grade of C-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for XERS?
The average analyst price target for Xeris Biopharma Holdings, Inc. (XERS) is $14.00 from 11 analysts, which is +56.4% versus the recent price of $8.95.
What is XERS's Piotroski score?
Xeris Biopharma Holdings, Inc. (XERS) has a Piotroski F-Score of 5 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.